FcRH5/FcRL5, His, Human

FcRH5/FcRL5, His, Human

FcRH5 is a cell surface marker enriched on malignant plasma cells when compared to other hematologic malignancies and normal tissues. DFRF4539A is an anti-FcRH5 antibody-drug conjugated to monomethyl auristatin E (MMAE), a potent anti-mitotic agent.
Z05281
¥72,752.00

Ask us a question
Product Introduction
Species Human
Protein Construction
FcRH5/FcRL5 (Gln16-Gly851)
Accession # Q96RD9-1		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized FcRH5/FcRL5, His, Human at 1μg/ml (100 μl/well) on the plate can bind Anti­FcRH5 Antibody, hFc Tag. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 92.38 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 120-140 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Background
Target Background FcRH5 is a cell surface marker enriched on malignant plasma cells when compared to other hematologic malignancies and normal tissues. DFRF4539A is an anti-FcRH5 antibody-drug conjugated to monomethyl auristatin E (MMAE), a potent anti-mitotic agent.
Synonyms FcR-like protein 5; FcRH5; FcRL5; BXMAS1; CD307; CD307e; IFGP5; IRTA2

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.